{"organizations": [], "uuid": "7cdbd0e4dbdb8e8868a1963c2fce9f2db6904b23", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eu-medicines-agency-recommendation/brief-eu-medicines-agency-recommendations-for-january-2018-idUSFWN1PL0SA", "country": "US", "domain_rank": 408, "title": "BRIEF-EU Medicines Agency Recommendations For January 2018‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-26T14:21:00.000+02:00", "replies_count": 0, "uuid": "7cdbd0e4dbdb8e8868a1963c2fce9f2db6904b23"}, "author": "", "url": "https://www.reuters.com/article/brief-eu-medicines-agency-recommendation/brief-eu-medicines-agency-recommendations-for-january-2018-idUSFWN1PL0SA", "ord_in_thread": 0, "title": "BRIEF-EU Medicines Agency Recommendations For January 2018‍​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-eu medicines agency", "sentiment": "negative"}, {"name": "brief-eu medicines agency recommendations", "sentiment": "negative"}, {"name": "reuters staff  j", "sentiment": "neutral"}, {"name": "eu medicines agency", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 21 PM / in 13 minutes BRIEF-EU Medicines Agency Recommendations For January 2018‍​ Reuters Staff \nJan 26 (Reuters) - EU Medicines Agency: * EU MEDICINES AGENCY RECOMMENDATIONS FOR JANUARY 2018‍​ \n* EU MEDICINES AGENCY RECOMMENDS APPROVAL OF GLAXOSMITHKLINE‘S SHINGLES DRUG SHINGRIX‍​ \n* EU MEDICINES AGENCY RECOMMENDS APPROVAL OF MERCK & CO AND PFIZER INC DIABETES DRUG STEGLATRO \n* EU MEDICINES AGENCY RECOMMENDS APPROVAL OF ROCHE HOLDING'S HAEMOPHILIA DRUG HEMLIBRA‍​ Source text ID: ( bit.ly/2DE0XXt ) Further company coverage:", "external_links": [], "published": "2018-01-26T14:21:00.000+02:00", "crawled": "2018-01-26T14:39:35.025+02:00", "highlightTitle": ""}